Fig. 5From: Role of PARP inhibitors beyond BRCA mutation and platinum sensitivity in epithelial ovarian cancer: a meta-analysis of hazard ratios from randomized clinical trialsForest plot showing overall survival in PARP inhibitor arm (case) and chemotherapy/placebo arm in platinum-resistant ovarian cancer (control); A overall population; B BRCAmutated populationBack to article page